Early trials of the drug VIR-5500 showed it shrinking tumours in some patients ...

Credit: Getty Images This clinical overview details the latest evidence-based strategies for diagnosing and treating symptoms of benign prostatic hyperplasia in men. Familial clustering studies ...

Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

Prostate enlargement, which is called Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement and is common in ageing men. As the prostate enlarges, it compresses the urethra and interferes ...

Dr. Kevin Zorn, MD, FRCSC, FACS, Urologist, discusses first line medications to treat BPH. After the Supreme Court's tariff ruling, here's what could be next for stocks Pentagon blocked from using UK ...

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

For patients with prostate cancer, concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs does not increase risks for thrombosis or bleeding.

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...

A new drug for advanced prostate cancer has shown promise in early trials experts have said, with the medication shrinking tumors in some patients. Prostate cancer is the most common cancer among men ...